You can access the annual and quarterly cash flow statements of Avalyn Pharma Ord Shs (Proposed) to evaluate its financial soundness and stability.
Quarterly
Quarterly+Annual
Quarterly
Annual
YOY
Hide blank rows
FY2026Q1
Operating cash flows (indirect method)
Cash flow from continuing operating activities
---29.89M
Net income from continuing operations
---26.87M
Operating gains losses
--63.00K
Other non-cash items
---123.00K
Change in working capital
---4.16M
-Change in prepaid expenses
---508.00K
-Change in other current assets
--0.00
Cash from non-recurring investing activities
Cash from operating activities
---29.89M
Investing cash flow
Net cash from continuing investing activities
--318.00K
Capital expenditures
--318.00K
Net cash flow from disposal of fixed assets
--318.00K
Net cash flow from investment products
--55.34M
Net cash flow from other investing activities
--0.00
Cash from non-current investing activities
Net cash flow from investing activities
--55.02M
Financing cash flow
Cash flow from continuous financing activities
--14.86M
Net cash flow from debt Issuance/repayment
--15.00M
Proceeds from stock option exercised by employees
--25.00K
Net cash flow from other financing activities
---163.00K
Net cash from non-recurrent financing activities
Net cash from financing activities
--14.86M
Net cash flow
Beginning cash balance
--52.31M
Current period cash flow changes
--39.99M
Ending cash balance
--92.31M
Free cash flow
---30.21M
Currency unit
USD
Audit opinions
--
FAQs
What is the cash flow statement?
This report tracks the movement of cash into and out of the business, covering operating, investing, and financing activities. It highlights how well the company manages cash to support growth and meet its obligations.